<DOC>
	<DOCNO>NCT02886559</DOCNO>
	<brief_summary>Despite advance understand complexity acute myeloid leukaemia ( AML ) , treatment refractory relapse AML ( rrAML ) remain daunt clinical challenge.The investigator design new regimen , include chidamide , decitabine , aclarubincin , cytarabine G-CSF , treat rrAML .</brief_summary>
	<brief_title>Chidamide Plus DCAG Relapsed/Refractory AML</brief_title>
	<detailed_description />
	<criteria>Men woman whose age 18 less 59； Patients diagnose AML accord 2008 WHO ( WHO ) myeloid malignant disease diagnosis standard ; Patients relapse remission achieve remission least two cycle systemic therapy ( include chemotherapy , hematopoietic stem cell transplantation , etc . ) ; ECOG performance status 03 ; Expected survival time ˃ 3 month ; Patients without serious heart , lung , liver , kidney disease ; Patients receive radiotherapy , chemotherapy , target therapy hematopoietic stem cell transplantation treatment within 4 week prior enrollment ; Patients able understand willing sign inform consent . Patients allergy study drug drug similar chemical structure ; ; Pregnancy , lactation woman woman childbearing age want practice effective method contraception ; Active infection ; Drug abuse , longterm alcohol abuse affect result evaluation patient ; Patients mental disorder condition obtain informed consent , meet requirement study treatment procedure ; Patients clinical significant QTc interval prolongation history ( male &gt; 450ms . Female &gt; 470ms ) , ventricular heart tachycardia ( VT ) atrial fibrillation ( AF ) , II degree heart block , myocardial infarction attack ( MI ) within 1 year prior enrollment , congestive heart failure ( CHF ) , patient coronary heart disease clinical symptom need drug treatment . Cardiac ultrasound show diastolic pericardial fluid dark area width ˃ 10mm ; Patients receive organ transplantation ; Active bleed Patients new thrombosis , embolism , cerebral hemorrhage diseases medical history patient within 1 year prior enrollment ; The main organ surgery less 6 week ; Bone marrow hyperplasia WBC &lt; 2.0 * 10^9/L ; Liver function abnormality ( total bilirubin &gt; 1.5 time upper limit normal range , ALT / AST &gt; 2.5 time upper limit normal range patient liver involvement whose ALT / AST &gt; 1.5 time upper limit normal range ) , renal anomaly ( serum creatinine &gt; 1.5 time upper limit normal value ) ; Not suitable study accord investigator 's assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>demethylating agent</keyword>
	<keyword>chidamide</keyword>
</DOC>